Previous Close | 23.77 |
Open | 24.11 |
Bid | 26.01 x 3200 |
Ask | 27.12 x 3000 |
Day's Range | 22.24 - 24.33 |
52 Week Range | 20.60 - 99.27 |
Volume | |
Avg. Volume | 2,181,898 |
Market Cap | 2.035B |
Beta (5Y Monthly) | 1.92 |
PE Ratio (TTM) | 15.35 |
EPS (TTM) | 1.74 |
Earnings Date | Feb 08, 2022 - Feb 14, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 55.00 |
InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial Officer, will participate at the UBS Healthcare One-on-One Virtual Day on June 1st, 2022. To schedule a meeting, please contact your UBS representative or Miri Segal at msegal@ms-ir.com.
InMode's sales and profits have boomed, but you wouldn't know it from the company's share price.
Shares of medical device company InMode (NASDAQ: INMD) fell 32% in April, according to data provided by S&P Global Market Intelligence. On April 11, the company gave encouraging preliminary financial results for the first quarter of 2022. Oddly enough, prominent analysts applauded the Q1 results from InMode but lowered their expectations for the stock nevertheless.